Evaluating HER2 and AXL Inhibitors on Cell Survival

The CE48T/VGH cells, lapatinib-resistant sub-cells and Het-1A cells were plated on 96-well plates (8000 cells/well) and treated with the indicated amounts of AXL inhibitor, foretinib [37 (link)] (GSK1363089, provided by Santa Cruz Biotechnology, Inc. SC-364492) or HER2 inhibitors. The HER2 inhibitors included lapatinib, afatinib [38 (link)] (Tovok, provided by Boehringer Ingelheim, Taiwan), and AC480 [39 (link)] (BMS599626, synthesized by Selleckchem, S1056). After incubation for 72 hours, cell survival was determined by MTT assay as described previously [40 (link)–41 (link)].

Free full text: Click here

Hsieh M.S., Yang P.W., Wong L.F, & Lee J.M. (2016). The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma. Oncotarget, 7(24), 36956-36970.

Publication 2016

lapatinib foretinib afatinib BMS599626

Afatinib Assay Bms599626 Cell survival Cells Foretinib Gsk1363089 Her2 Inhibitors Lapatinib

Corresponding Organization : National Taiwan University Hospital

Other organizations : National Taiwan University

Top 5 similar protocols

Variable analysis

independent variables

AXL inhibitor, foretinib (GSK1363089)
HER2 inhibitors (lapatinib, afatinib (Tovok), AC480 (BMS599626))

dependent variables

Cell survival

control variables

Cell lines (CE48T/VGH cells, lapatinib-resistant sub-cells, Het-1A cells)
Cell density (8000 cells/well)
Incubation time (72 hours)

controls

Positive control: Not specified
Negative control: Not specified

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!